A truncated plasmid-encoded HIV-1 reverse transcriptase displays strong immunogenicity

Viral Immunology

Volumn 26, Issue 2, 2013, Pages 163-166

  Hallengärd, David ^a   Wahren, Britta ^a   Bråve, Andreas ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RNA DIRECTED DNA POLYMERASE;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG BINDING SITE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MULTIGENE FAMILY; NONHUMAN;

AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CYTOKINES; FEMALE; HIV REVERSE TRANSCRIPTASE; HIV-1; HLA-A2 ANTIGEN; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PLASMIDS; SEQUENCE DELETION; SPLEEN; VACCINES, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 84876133224     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2012.0083     Document Type: Article

References (22)

1. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008;372:1881-1893.
2. Goepfert PA, Elizaga ML, Sato A, et al. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis 2011;203:610-619.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009;361:2209-2220.
4. Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. 2011;PLoS One. 6:e19252.
5. Rollman E, Brave A, Boberg A, et al. The rationale behind a vaccine based on multiple HIV antigens. Microbes Infect 2005;7:1414-1423. (Pubitemid 41653487)
6. Bakari M, Aboud S, Nilsson C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 201129:8417-8428.
7. Sandstrom E, Nilsson C, Hejdeman B, et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008;198:1482-1490.
8. Isaguliants MG, Petrakova NN, Zuber B, et al. DNAencoding enzymatically active HIV-1 reverse transcriptase, but not the inactive mutant, confers resistance to experimental HIV-1 challenge. Intervirology 2000;43:288-293. (Pubitemid 32225700)
9. Starodubova E, Boberg A, IVanov A, et al. Potent crossreactive immune response against the wild-type and drugresistant forms of HIV reverse transcriptase after the chimeric gene immunization. Vaccine 2010;28:1975-1986.
10. Starodubova E, Boberg A, Kashuba EV, et al. HIV-1 reverse transcriptase targeted for proteasomal degradation as a prototype vaccine against drug-resistant HIV-1. Vaccine 2006;24: 4541-4547. (Pubitemid 43776778)
11. Starodubova ES, Boberg A, Litvina M, et al. 2008 HIV-1 reverse transcriptase artificially targeted for proteasomal degradation induces a mixed Th1/Th2-type immune response. Vaccine 2008;26:5170-5176.
12. Walker LE, Vang L, Shen X, et al. Design and preclinical development of a recombinant protein and DNA plasmid mixed format vaccine to deliver HIV-derived T-lymphocyte epitopes. Vaccine 2009;27:7087-7095.
13. Hallengard D, Haller BK, Petersson S, et al. Increased expression and immunogenicity of HIV-1 protease following inactivation of the enzymatic activity. Vaccine 2011;29: 839-848.
14. Gudmundsdotter L, Wahren B, Haller BK, et al. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial. Vaccine 2011;29:5558-5566.
15. Ljungberg K, Rollman E, Eriksson L, et al. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 2002;302: 44-57. (Pubitemid 35356854)
16. Isaguliants MG, Pokrovskaya K, Kashuba VI, et al. Eukaryotic expression of enzymatically active human immunodeficiency virus type 1 reverse transcriptase. FEBS Lett 1999;447:232-236. (Pubitemid 29146092)
17. Roos AK, Eriksson F, Timmons JA, et al. Skin electroporation: Effects on transgene expression, DNA persistence and local tissue environment. PLoS One 2009;4:e7226.
18. Pascolo S, Bervas N, Ure JM, et al. HLA-A2.1-restricted education and cytolytic activity of CD8( + ) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997;185:2043-2051. (Pubitemid 27265987)
19. Hallengard D, Haller BK, Maltais AK, et al. Comparison of plasmid vaccine immunization schedules using intradermal in vivo electroporation. Clin Vaccine Immunol 2011;18: 1577-1581.
20. Grosjean H, Fiers W. Preferential codon usage in prokaryotic genes: The optimal codon-anticodon interaction energy and the selective codon usage in efficiently expressed genes. Gene 1982;18:199-209. (Pubitemid 13232993)
21. Kjerrstrom A, Hinkula J, Engstrom G, et al. Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines. Virology 2001;284:46-61. (Pubitemid 32476695)
22. Brave A, Ljungberg K, Boberg A, et al. Reduced cellular immune responses following immunization with a multigene HIV-1 vaccine. Vaccine 2006;24:4524-4526. (Pubitemid 43776765)